ReviewParasite immunology2016
Approaches to vaccination against Theileria parva and Theileria annulata.
Review in Parasite immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Theileria parva genetics, prevalence and vaccination practices in Zimbabwe and the African region and the prospects for vaccine development: a systematic review.Veterinary research communications · 2025Pooled it
- Epigenetic landscape of the H3K27me3 mark in macrophages transformed by Theileria annulata.Communications biology · 2026Article
- Comparison of theParasitology · 2026Article
- The Culture Technology for the Transforming Parasite-Theileria Annulata Schizont-Infected Cells: Past-Present-Perspective.Acta parasitologica · 2025Review
- Expanding the molecular understanding of Theileria infections in cattle and yaks from Gansu and Qinghai, China.Parasitology research · 2025Article
- Molecular characterization of a synthetic neutralizing antibody targeting p67 of Theileria parva.Protein science : a publication of the Protein Society · 2025Article
- Design and evaluation of vaccines for the control of the etiological agent of East Coast fever.Parasites & vectors · 2024Review
- Comparative transcriptional analysis identifies genes associated with the attenuation of Theileria parva infected cells after long-term in vitro culture.Scientific reports · 2024Article
- Can the Revolution in mRNA-Based Vaccine Technologies Solve the Intractable Health Issues of Current Ruminant Production Systems?Vaccines · 2024Review
- Current vaccines, experimental immunization trials, and new perspectives to control selected vector borne blood parasites of veterinary importance.Frontiers in veterinary science · 2024Review
- Humoral and cellular immunity in response to anFrontiers in immunology · 2024Article
- Prevalence and Risk Factors Associated withPathogens (Basel, Switzerland) · 2023Article
- Article
- Development of a dual vaccine against East Coast fever and lumpy skin disease.Frontiers in immunology · 2023Article
- Article
- Genetic Resistance of Bovines to Theileriosis.Animals : an open access journal from MDPI · 2022Review
- Theileria annulata SVSP455 interacts with host HSP60.Parasites & vectors · 2022Article
- Systematic Determination of TCR-Antigen and Peptide-MHC Binding Kinetics among Field Variants of aJournal of immunology (Baltimore, Md. : 1950) · 2022Article
- Characterization of a Novel ChimericVaccines · 2022Article
- Design and immunological evaluation of two-component protein nanoparticle vaccines for East Coast fever.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Despite having different cell tropism, the pathogenesis and immunobiology of the diseases caused by Theileria parva and Theileria annulata are remarkably similar. Live vaccines have been available for both parasites for over 40 years, but although they provide strong protection, practical disadvantages have limited their widespread application. Efforts to develop alternative vaccines using defined parasite antigens have focused on the sporozoite and intracellular schizont stages of the parasites. Experimental vaccination studies using viral vectors expressing T. parva schizont antigens and T. parva and T. annulata sporozoite antigens incorporated in adjuvant have, in each case, demonstrated protection against parasite challenge in a proportion of vaccinated animals. Current work is investigating alternative antigen delivery systems in an attempt to improve the levels of protection. The genome architecture and protein-coding capacity of T. parva and T. annulata are remarkably similar. The major sporozoite surface antigen in both species and most of the schizont antigens are encoded by orthologous genes. The former have been shown to induce species cross-reactive neutralizing antibodies, and comparison of the schizont antigen orthologues has demonstrated that some of them display high levels of sequence conservation. Hence, advances in development of subunit vaccines against one parasite species are likely to be readily applicable to the other.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.